Pipeline

Virogin is dedicated to bringing next-generation immuno-oncolytic therapeutics to the clinic through our robust pipeline.

Product

HSV-1 Backbone

Enhanced Replication

Payloads

Core

Additional

Phase

Discovery

IND-enabling

Phase 1

Phase 2

Product

First Item

HSV-1 Backbone

Enhanced Replication

Payloads

Core

Payloads

Additional

Phase

Product

VG161*

HSV-1 Backbone

Attenuated (ICP 34.5 deletion)

Enhanced Replication

Payloads

Core

IL-12, IL-15, IL-15Rα

Payloads

Additional

PD-L1 blocking peptide

Phase

Product

VG201

HSV-1 Backbone

Engineered to enhance replication in tumors (Transcription & Translation Dual Regulation [TTDR])

Enhanced Replication

CEA+ tumors

Payloads

Core

IL-12, IL-15, IL-15Rα

Payloads

Additional

Phase

Product

VG203

HSV-1 Backbone

Engineered to enhance replication in tumors (Transcription & Translation Dual Regulation [TTDR])

Enhanced Replication

CXCR4+ tumors

Payloads

Core

IL-12, IL-15, IL-15Rα

Payloads

Additional

Phase

Product

VG301

HSV-1 Backbone

Engineered to enhance replication in tumors (Transcription & Translation Dual Regulation [TTDR])

Enhanced Replication

CEA+ tumors

Payloads

Core

IL-12, IL-15, IL-15Rα

Payloads

Additional

T-cell engager payload against a tumor-associated antigen

Phase

VGXXX

Multiple programs evaluating differentiated HSV-1 backbones and payloads with complementary mechanisms of action

HSV-1 = Oncolytic herpes simplex virus type 1; ICP = Infected cell protein; IND = Investigational New Drug; CEA = Carcinoembryonic antigen; IL = Interleukin